COVID-19 | FiercePharma

COVID-19

Follow all of our coverage around coronavirus and COVID-19. Due to the fast nature of this pandemic, we are publishing additional stories and a daily PM newsletter. You can also follow our coverage on Twitter @FiercePharma.

Mostly quiet till now, Merck unveils a trio of COVID-19 deals

by Eric Sagonowsky

Tuesday, May 26, 2020

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

Detailed remdesivir data confirm its benefits and limitations

by Angus Liu

Tuesday, May 26, 2020

The 1,063-patient study showed remdesivir’s benefits look the greatest for individuals in the middle of the disease severity spectrum.

Sanofi, Regeneron's Dupixent shows promise in esophagitis trial

by Kyle Blankenship

Tuesday, May 26, 2020

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.

CanSino, WuXi, Fujifilm and more—FiercePharmaAsia

by Angus Liu

Friday, May 22, 2020

CanSino licenses an mRNA coronavirus vaccine. WuXi Biologics set to build $60 million U.S. facility. A Fujifilm drug reportedly fails in COVID-19.

U.K. grants new vaccine manufacturing center £131M

by Eric Sagonowsky

Thursday, May 21, 2020

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

How Civica helped Phlow nab a $354M COVID-19 manufacturing deal

by Arlene Weintraub

Thursday, May 21, 2020

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.

AstraZeneca scores $1.2B from U.S. for COVID vaccines

by Eric Sagonowsky

Thursday, May 21, 2020

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

Will large generics firms bring drug manufacturing to the U.S.?

by Angus Liu

Thursday, May 21, 2020

After the Trump administration tapped little-known Phlow to make drugs on U.S. soil, one analyst suspects large generics players will follow.

Gilead views remdesivir as a 'multi-year commercial opportunity'

by Angus Liu

Wednesday, May 20, 2020

Gilead is already getting requests for national stockpiling of remdesivir, which could mean revenues for years to come.

AstraZeneca in talks to supply COVID-19 vaccine worldwide

by Eric Sagonowsky

Tuesday, May 19, 2020

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.